Mafosfamide as a New Anticancer Agent: Preclinical Investigations and Clinical Trials

作者：Mazur Lidia^*; Opydo Chanek Malgorzata; Stojak Marta; Wojcieszek Katarzyna

来源：Anticancer Research, 2012, 32(7): 2783-2789.

• Mafosfamide
• new anticancer agent
• review
• neoplastic meningitis
• oxazaphosphorines

Mafosfamide (4-thioethane sulfonic acid salt of 4-hydroxy-cyclophosphamide, MAF) belongs to a new generation of the oxazaphosphorine agents. MAP is a cyclophosphamide analog which spontaneously degrades to 4-hydroxy-cyclophosphamide. The effects of MAF on various types of cancer cells were determined during preclinical investigations and clinical trials. The positive results from in vitro and in vivo anticancer studies promoted MAP to a good candidate for phase I trials. Clinical experience with intrathecal MAF, used for patients with neoplastic meningitis due to leukemia, lymphoma, and solid tumors, indicated good tolerability and efficacy. The recommended phase II doses of intrathecally administered MAP were determined. Clinical trials using intrathecal MAP are now underway. To obtain a better therapeutic index, a strategy to alternate dosing between the intraventricular and intralumbar routes is also being tested. MAP is an attractive agent for regional cancer therapy. The current available knowledge on MAP as a new anticancer agent is based on a collection of the original published studies, conference abstracts and relevant articles.

• 出版日期2012-7